 1. Target Disease Exceptions: a. Subjects with active CNS metastases are excluded. Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline except for residual signs or symptoms related to the CNS treatment for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of 10 mg daily prednisone or equivalent for 2 weeks. b. Subjects with carcinomatous meningitis. 